Furosemide increases plasma oxypurinol without lowering serum urate-A complex drug interaction: Implications for clinical practice

Rheumatology (United Kingdom)

Volumn 51, Issue 9, 2012, Pages 1670-1676

  Stamp, Lisa K ^a   Barclay, Murray L ^a   O'donnell, John L ^b   Zhang, Mei ^b   Drake, Jill ^b   Frampton, Christopher ^a   Chapman, Peter T ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Allopurinol; Furosemide; Gout; Oxypurinol; Serum urate

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; DIURETIC AGENT; DRUG METABOLITE; FUROSEMIDE; LOSARTAN; OXIPURINOL; URIC ACID;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CASE CONTROL STUDY; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIURETIC THERAPY; DRUG METABOLISM; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERURICEMIA; ISCHEMIC HEART DISEASE; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PLASMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; URINARY EXCRETION; URINE LEVEL;

ADULT; AGED; ALLOPURINOL; AREA UNDER CURVE; CASE-CONTROL STUDIES; DIURETICS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FUROSEMIDE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; OXYPURINOL; TREATMENT OUTCOME; URIC ACID; URINATION;

EID: 84865346674     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes091     Document Type: Article

References (24)

1. Grundy S, Cleeman J, Daniels S et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation 2005;112: 2735-52.
2. Choi H, Ford E, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the third National Health and Nutrition Examination Survey. Arthritis Care Res 2007;57:109-15.
3. Annemans L, Spaepen E, Gaskin M et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6.
4. Reyes A. Cardiovascular drugs and serum uric acid. Cardiovasc Drug Ther 2003;17:397-414.
5. Gurwitz J, Kalish S, Bohn R et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 1997; 50:953-9.
6. York M, Hunter D, Chaisson C et al. Recent thiazide use and the risk of acute gout: the online case-crossover gout study. Arthritis Rheum 2004;50:S341.
7. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of furosemide on renal excretion of oxypurinol and purine bases. Metabolism 2001;50:241-5.
8. Stamp L, Barclay M, O'Donnell J et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharm Ther 2011;90:392-8.
9. Stamp L, O'Donnell J, Zhang M et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment. Arthritis Rheum 2011;63:412-21.
10. Wallace S, Robinson H, Masi A et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
11. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70.
12. Simkin P. When, why, and how should we quantify the excretion rate of urinary uric acid? J Rheumatol 2001;28: 1207-10.
13. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
14. El-Sheikh A, van den Heuvel J, Koenderink J, Russel F. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Clin Pharmacol 2008;155:1066-75.
15. Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I. Involvement of uric acid transporter in increased renal clearance of the xanthiine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos 2005;33:1791-5.
16. So A, Thorens B. Uric acid transport and disease. J Clin Invest 2010;120:1791-9.
17. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of furosemide on the plasma concentration and urinary excretion of purine bases, adenosine, and uridine. Metabolism 2000;49:886-9.
18. Hande K, Noone R, Stone W. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
19. Wurzner G, Gersterb J-C, Chioleroa A et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1855-60.
20. Soffer B, Wright J, Pratt J et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-7.
21. Chanard J, Toupance O, Lavaud S et al. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 2003;18:2147-53.
22. Milionis H, Kakafika A, Tsouli S et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidaemia. Am Heart J 2004;148: 635-40.
23. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol 2001;28:2294-7.
24. Takahashi S, Moriwaki Y, Yamamoto T et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003;62:572-5.